文献速递传染病防控与疫情报告免疫规划

鼻内免疫接种结合M细胞靶向配体Co4B的中东呼吸综合征冠状病毒抗原可增强抗原特异性黏膜和全身免疫并抵御感染

Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection.
PubMed 文献 · Vaccine · 2021-12-30

本研究将Co4B配体与中东呼吸综合征冠状病毒(MERS-CoV)刺突蛋白受体结合域(S-RBD)偶联,经鼻内免疫C57BL/6小鼠和人二肽基肽酶4转基因(hDPP4-Tg)小鼠。与未偶联S-RBD相比,S-RBD-Co4B高度诱导抗原特异性黏膜IgA、全身IgG和病毒中和活性,并诱导脾和肺T细胞免疫;hDPP4-Tg小鼠免疫后病毒攻击时组织免疫细胞浸润减少,保护更好、更易存活、体重丢失更少。作者认为S-RBD-Co4B可作为鼻内MERS-CoV疫苗候选。

要点

  • S-RBD-Co4B鼻内免疫较未偶联S-RBD高度诱导黏膜IgA、全身IgG和病毒中和活性。
  • S-RBD-Co4B鼻内免疫诱导脾和肺的抗原特异性T细胞介导免疫。
  • hDPP4-Tg小鼠免疫S-RBD-Co4B后病毒攻击时组织免疫细胞浸润减少,保护更好、更易存活、体重丢失更少。

核心结论

  • 作者认为S-RBD-Co4B可作为针对MERS-CoV感染的鼻内疫苗候选。

研究设计与样本

  • 将Co4B配体偶联至MERS-CoV刺突蛋白受体结合域(S-RBD),经鼻内免疫C57BL/6小鼠和人二肽基肽酶4转基因(hDPP4-Tg)小鼠。

主要发现

  • 与未偶联S-RBD免疫小鼠相比,S-RBD-Co4B免疫小鼠高度诱导抗原特异性黏膜IgA、全身IgG及病毒中和活性。
  • S-RBD-Co4B鼻内免疫小鼠的脾和肺中诱导抗原特异性T细胞介导免疫。
  • hDPP4-Tg小鼠鼻内免疫S-RBD-Co4B后,病毒攻击小鼠组织免疫细胞浸润减少。
  • S-RBD-Co4B免疫小鼠保护更好、更易存活、体重丢失更少。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Middle East respiratory syndrome (MERS) is a threat to public health worldwide. A vaccine against the causative agent of MERS, MERS-coronavirus (MERS-CoV), is urgently needed. We previously identified a peptide ligand, Co4B, which can enhance antigen (Ag) delivery to the nasal mucosa and promote Ag-specific mucosal and systemic immune responses following intranasal immunization. MERS-CoV infects via the respiratory route; thus, we conjugated the Co4B ligand to the MERS-CoV spike protein receptor-binding domain (S-RBD), and used this to intranasally immunize C57BL/6 and human dipeptidyl peptidase 4-transgenic (hDPP4-Tg) mice. Ag-specific mucosal immunoglobulin (Ig) A and systemic IgG, together with virus-neutralizing activities, were highly induced in mice immunized with Co4B-conjugated S-RBD (S-RBD-Co4B) compared to those immunized with unconjugated S-RBD. Ag-specific T cell-mediated immunity was also induced in the spleen and lungs of mice intranasally immunized with S-RBD-Co4B. Intranasal immunization of hDPP4-Tg mice with S-RBD-Co4B reduced immune cell infiltration into the tissues of virus-challenged mice. Finally, S-RBD-Co4B-immunized mice exhibited were better protected against infection, more likely to survive, and exhibited less body weight loss. Collectively, our results suggest that S-RBD-Co4B could be used as an intranasal vaccine candidate against MERS-CoV infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yang YL, Kim J, Jeong Y, et al. Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection. Vaccine. 2021. PMID: 34991928. doi:10.1016/j.vaccine.2021.12.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。